Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione
Public ClinicalTrials.gov record NCT00228644. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione and Cysteine.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Availability of sulfur amino acids (SAA) is critical for glutathione/glutathione disulfide (GSH/GSSG) and cysteine/cystine (CYS/CYSS) redox in vivo and for many other physiologic functions including protein synthesis, nitrogen balance, digestion, osmotic regulation, detoxification, hormonal regulation, biologic methylations, and cell growth regulation. GSH conjugation and sulfate conjugation represent quantitatively important pathways for chemical detoxification, which imposes substantial burden upon SAA supply. The primary hypothesis is that SAA deficient diet and acetaminophen (APAP) administration will perturb Cys metabolism and GSH redox homeostasis in human plasma and urinary output of SAA metabolites. Because both of these variations affect SAA homeostasis, it is believed that the combination of these treatments will produce an interactive effect in which 2-day SAA deficiency will alter APAP metabolism, APAP will affect SAA homeostasis, and the treatments together will alter the global metabolic profile, as measured by 1H-NMR spectroscopy.
Study identification
- NCT ID
- NCT00228644
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Months to 40 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2005 (Type not available)
- Primary completion
- Not listed
- Completion
- Jan 2009 (Actual)
- Last update posted
- Jan 30, 2009
2005 – 2009
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00228644, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2009 · Synced Oct 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00228644 live on ClinicalTrials.gov.